La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Haleon Gestione

Gestione criteri di controllo 0/4

Haleon's Il CEO è Brian McNamara, nominato in Jul2021, e ha un mandato di 3.08 anni. la retribuzione annua totale è £ 5.76M, composta da 21.7% di stipendio e 78.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.014% delle azioni della società, per un valore di £ 4.67M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 0.8 anni e 2.1 anni.

Informazioni chiave

Brian McNamara

Amministratore delegato

UK£5.8m

Compenso totale

Percentuale dello stipendio del CEO	21.7%
Mandato del CEO	3.2yrs
Proprietà del CEO	0.01%
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	2.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Brian McNamara rispetto agli utili di Haleon?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	UK£1b
Mar 31 2024	n/a	n/a	UK£1b
Dec 31 2023	UK£6m	UK£1m	UK£1b
Sep 30 2023	n/a	n/a	UK£1b
Jun 30 2023	n/a	n/a	UK£1b
Mar 31 2023	n/a	n/a	UK£1b
Dec 31 2022	UK£2m	UK£719k	UK£1b

Compensazione vs Mercato: La retribuzione totale di Brian ($USD 7.55M ) è superiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 5.59M ).

Compensazione vs guadagni: La retribuzione di Brian è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Brian McNamara (58 yo)

3.2yrs

Mandato

UK£5,763,000

Compensazione

Mr. Brian James McNamara serves as Independent Director at Mondelez International, Inc. since February 01, 2024. He serves as Chief Executive Officer at Haleon plc and serves as its Executive Director sinc...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Brian McNamara	CEO & Executive Director	3.2yrs	UK£5.76m	0.014% £ 5.0m
Tobias Hestler	CFO & Executive Director	2.8yrs	UK£2.05m	0.00071% £ 256.6k
Claire Dickson	Chief Digital & Technology Officer	no data	Nessun dato	Nessun dato
Sonya Ghobrial	Head of Investor Relations	no data	Nessun dato	Nessun dato
Adrian Morris	General Counsel	less than a year	Nessun dato	Nessun dato
Tamara Rogers	Chief Marketing Officer	2.8yrs	Nessun dato	0.00031% £ 112.1k
Line De Decker	Chief Human Resources Officer	less than a year	Nessun dato	Nessun dato
Filippo Lanzi	President of EMEA & LatAm	no data	Nessun dato	0.00076% £ 274.7k
Keith Choy	President of Asia Pacific	no data	Nessun dato	0.00062% £ 224.1k
Lisa Paley	President of North America	no data	Nessun dato	0.00043% £ 155.4k
Franck Riot	Chief R&D Officer	no data	Nessun dato	0.00024% £ 86.8k
Bjorn Timelin	Head of Strategy	less than a year	Nessun dato	Nessun dato

0.9yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di HLNL non è considerato esperto (durata media 0.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Brian McNamara	CEO & Executive Director	2.3yrs	UK£5.76m	0.014% £ 5.0m
Tobias Hestler	CFO & Executive Director	2.3yrs	UK£2.05m	0.00071% £ 256.6k
Dame Cox	Independent Non-Executive Director	2.2yrs	UK£125.40k	Nessun dato
Manvinder Banga	Senior Independent Non-Executive Director	2.2yrs	UK£145.60k	0.0036% £ 1.3m
Tracy Clarke	Independent Non-Executive Director	2.2yrs	UK£135.20k	0.00014% £ 50.6k
Deirdre Mahlan	Independent Non-Executive Director	2.2yrs	UK£149.20k	0.00088% £ 318.1k
Alan James Stewart	Independent Non-Executive Director	no data	Nessun dato	Nessun dato
David Lewis	Independent Non-Executive Chair	2.3yrs	UK£705.60k	0.0010% £ 375.9k
David Denton	Non-Executive Director	1.5yrs	UK£200.00	Nessun dato
Bryan Supran	Non-Executive Director	2.2yrs	UK£6.10k	0.00055% £ 198.8k
Marie-Anne Aymerich	Independent Non-Executive Director	2.2yrs	UK£123.00k	0.00031% £ 112.1k
Asmita Dubey	Independent Non-Executive Director	2.2yrs	UK£96.80k	Nessun dato

2.2yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di HLNL non è considerato esperto (durata media del mandato 2.1 anni), il che suggerisce un nuovo consiglio.

Haleon Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Haleon plc Announces Directorate Change

Haleon plc Announces Chief Financial Officer Changes

Haleon plc, Annual General Meeting, May 08, 2024

High number of new and inexperienced directors

Independent Non-Executive Chair recently bought UK£100k worth of stock

Haleon plc Announces Board Changes

Recent updates

Haleon Announces the Launch of Eroxon®?, the First and Only Fda Cleared Otc Gel for Erectile Dysfunction, Available for U.S. Pre Order Without A Prescription

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024.

Haleon plc (LSE:HLN) commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024.

Haleon plc Provides Earnings Guidance for the Fiscal Year 2024

Haleon plc to Report Fiscal Year 2024 Results on Mar 05, 2025

Dr. Reddy'S Laboratories S.A. signed a definitive agreement to acquire Northstar Switzerland SARL from Haleon plc (LSE:HLN) for £500 million.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

First quarter 2024 earnings released: EPS: UK£0.046 (vs UK£0.042 in 1Q 2023)

Haleon plc Announces Directorate Change

Now 20% overvalued after recent price rise

Haleon plc Announces Chief Financial Officer Changes

Haleon plc has completed a Follow-on Equity Offering in the amount of $3.1 billion.

Haleon plc has filed a Follow-on Equity Offering.

Haleon plc has filed a Follow-on Equity Offering.

Sensodyne Introduces New Triple Action Formula: 'Sensitivity Gum & Enamel'

Upcoming dividend of UK£0.042 per share

Final dividend increased to UK£0.042

Full year 2023 earnings released: EPS: UK£0.11 (vs UK£0.12 in FY 2022)

Haleon plc, Annual General Meeting, May 08, 2024

Now 23% overvalued

Haleon plc Proposes Final Dividend for Fiscal Year 2023, Payable on 16 May 2024

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

Third quarter 2023 earnings released: EPS: UK£0.04 (vs UK£0.037 in 3Q 2022)

Haleon plc to Report Fiscal Year 2023 Results on Feb 29, 2024

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

Upcoming dividend of UK£0.018 per share at 1.1% yield

Second quarter 2023 earnings released: EPS: UK£0.032 (vs UK£0.019 in 2Q 2022)

Haleon plc Provides Earnings Guidance for the Fiscal Year 2023

Haleon Reportedly Exploring Sale of Nicotine Gum Business

First quarter 2023 earnings released: EPS: UK£0.042 (vs UK£0.037 in 1Q 2022)

High number of new and inexperienced directors

Independent Non-Executive Chair recently bought UK£100k worth of stock

Full year 2022 earnings released: EPS: UK£0.12 (vs UK£0.15 in FY 2021)

Haleon plc Announces Board Changes

Third quarter 2022 earnings released

Haleon plc Provides Revenue Guidance for Fiscal 2022

Second quarter 2022 earnings released

Haleon plc Provides Revenue Guidance for Fiscal 2022

Haleon Introduces Advil PLUS Acetaminophen to Canadians, Combining Two Trusted Pain Relievers into One Convenient Tablet

Haleon plc to Report First Half, 2022 Results on Sep 19, 2022

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media